Predictive Value of Pre-TAVI Infrahissian Conduction Time in the Occurrence of Complete Atrioventricular Block (TAVHIS)
Predictive Value of Pre-Transcatheter Aortic Valve Implantation (TAVI) Infrahissian Conduction Time in the Occurrence of Complete Atrioventricular Block in Patients With Preoperative Right Bundle Branch Block
Sponsor: Euraxi Pharma
Terminated
The sponsor, in consultation with the coordinating investigator, had decided to stop enrolment prematurely because the enrolment rate would not have made it possible to reach the target of 142 patients without increasing the duration of the study
Other terminated trials from Euraxi Pharma
Listed as NCT05714579, this NA trial focuses on Aortic Stenosis, Severe and remains terminated or withdrawn. Sponsored by Euraxi Pharma, it has been updated 6 times since 2023, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Apr 2025 — Present [monthly]
Terminated NA
-
Mar 2025 — Apr 2025 [monthly]
Terminated NA
Status: Recruiting → Terminated
-
Sep 2024 — Mar 2025 [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Jul 2023 — Jul 2024 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Mar 2023 — Jul 2023 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Euraxi Pharma
- GCS Ramsay Santé pour l'Enseignement et la Recherche
For direct contact, visit the study record on ClinicalTrials.gov .